Navigation Links
Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010
Date:9/13/2010

hibitor, PCI-27483, is currently being evaluated in a multicenter Phase I/II randomized study in patients with locally advanced or metastatic pancreatic cancer. As planned, we have completed the Phase I portion of this Phase I/II trial and have successfully advanced to Phase II. In the Phase II portion of this study each pancreatic cancer patient will receive a maximum of 12 weeks of treatment with gemcitabine alone or gemcitabine plus PCI-27483. As of to date we have dosed 11 pancreatic cancer patients and the study continues enrolling in the randomized Phase II segment of the trial. We anticipate completing enrollment of 46 patients in the second half of 2011.
  • Histone deacetylase (HDAC) Inhibitor, PCI-24781, is the company's orally-bioavailable HDAC Inhibitor that disrupts DNA repair and contributes to tumor cell death. In 3 Phase I clinical trials, conducted in patients with hematologic or solid tumors, clinical response or control of tumor growth has been observed following single-agent therapy with our HDAC Inhibitor. Pharmacyclics' HDAC Inhibitor has demonstrated a good safety profile in approximately 90 patients treated so far; the main dose-limiting toxicity was a rapidly reversible thrombocytopenia, which we believe is related to the pharmacologic mechanism of action. The magnitude of thrombocytopenia can be attenuated by modification of the treatment schedule. The Phase II portion of our ongoing trial is continuing in patients with follicular and mantle cell lymphoma.  Results are anticipated in the second half of 2011. To date we have enrolled 7 follicular and 3 mantle cell patients; so far in this study 1 patient had a partial response and 4 patients have reported stable disease after 2 cycles.
  • The HDAC Inhibitor PCI-24781 has also shown synergy in preclinical testing with several approved cancer therapeutics. A Phase I/II trial in sarcoma patients is ongoing and is co-sponsored by prominent investigators at Massachuse
    '/>"/>

  • SOURCE Pharmacyclics
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

    Related medicine technology :

    1. Pharmacyclics Announces Data and Publication Characterizing Highly-Selective HDAC Inhibitor
    2. Pharmacyclics Announces Preclinical Results Supporting Development of Its Novel Btk Inhibitor in Immune Mediated Diseases
    3. Pharmacyclics Reports Multiple Presentations at AACR on Its HDAC and Selective HDAC Inhibitors
    4. Pharmacyclics Novel Factor VIIa Inhibitor Demonstrates Potential Inhibition of Tumor Growth in Multiple Types of Cancer
    5. Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma
    6. Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483
    7. Pharmacyclics, Inc. Announces Closing of a Private Financing With the Principals of Pacific Biopharma Group, Ltd.
    8. Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkins Lymphoma
    9. Pharmacyclics announces Global Strategic Alliance with Les Laboratoires Servier
    10. Pharmacyclics to Present at Merriman Curhan Fords Investor Summit 2009
    11. Pharmacyclics Announces Poster Presentations and Clinical Update at the 51st Annual Meeting of the American Society of Hematology
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/24/2014)...  Lazarus Effect, a medical device company focused ... facilitate removal of blood clots, announced today that ... issued a new patent (U.S. Patent Number 8,795,305) ... TM and ReCover TM devices. ... stent-retriever (stentriever) with an integrated, novel, cover-based protection ...
    (Date:7/24/2014)... , July 24, 2014 Consolidated Net ... Business Highlights   , India Business grew ... by 9.33% to Rs. 4,886.70 Mn Rest of World ... Europe Formulations Business grew by 34.53% to Rs. 977.26 Mn ... , Glenmark Pharmaceuticals Limited, the research-led global ...
    (Date:7/24/2014)... -- In any given hospital in the country at any ... one hospital-acquired infection, according to the Centers of Disease ... prove fatal. And as increased surveillance has shown that ... per year, infection control efforts have drifted to the ... stronger emphasis is being placed upon innovative and comprehensive ...
    Breaking Medicine Technology:Lazarus Effect Receives Notice of Allowance for New US Patent Covering Core Protection Technology 2Glenmark's Consolidated Revenue Increases by 20.08% to Rs. 14,869.40 Mn for Q1 FY 14 - 15 2Glenmark's Consolidated Revenue Increases by 20.08% to Rs. 14,869.40 Mn for Q1 FY 14 - 15 3Glenmark's Consolidated Revenue Increases by 20.08% to Rs. 14,869.40 Mn for Q1 FY 14 - 15 4Employees, Equipment and the Environment: Top Infection Prevention Focuses in Hospitals 2Employees, Equipment and the Environment: Top Infection Prevention Focuses in Hospitals 3
    ...  Medtronic, Inc, one of the world,s largest medical device ... U.S. Department of Justice (DOJ), the Office of the ... Services, and four relators in a qui tam suit ... in the U.S., including pacemakers and implantable cardioverter defibrillators ...
    ... A three-drug combination treatment for the blood cancer multiple myeloma ... patients, according to a multi-center study led by Andrzej ... the multiple myeloma program at the University of Chicago Medical ... of the phase I-II study on Dec. 12, 2011, ...
    Cached Medicine Technology:Settlement Announced in Medtronic Qui Tam Case 2Drug Combination Highly Effective for Newly Diagnosed Myeloma Patients, Study Finds 2Drug Combination Highly Effective for Newly Diagnosed Myeloma Patients, Study Finds 3
    (Date:7/24/2014)... for head and neck cancer (HNC). Evidence suggests certain cancers ... of HNC in patients with DM has not been well ... common type of cancer. It accounts for about 6 percent ... cases and 350,000 cancer deaths worldwide each year. , The ... the risk of HNC in patients with DM. The authors ...
    (Date:7/24/2014)... This year the Walk to End ... Jackson National Life, will be held on Saturday, September 20 ... Kids Fun Run at 7:50 am, the untimed 5k Run ... , “The Walk to End Alzheimer’s unites the entire community ... fight against this devastating disease, “stated Linda Mitchell, CEO and ...
    (Date:7/24/2014)... two or more equally positive outcomes experience paradoxical ... activity in different regions of the brain, according ... research scholar at the Princeton Neuroscience Institute at ... people rated the desirability of more than 300 ... at images of paired products with different or ...
    (Date:7/24/2014)... Memantine was initially developed by Merz to ... under the brand name Akatinol; it was later licensed to ... in the USA to Forest Labs as Namenda. Lundbeck reported ... In the US, Forest reported Namenda sales of USD 1.5 ... Australia and the European region has increased the competition from ...
    (Date:7/24/2014)... at Carnegie Mellon University, working with high-throughput data ... National Laboratory, have devised a computational method to ... breast cells turn malignant and as they respond ... analyzing how genes interact with each other in ... today by the online journal PLOS Computational ...
    Breaking Medicine News(10 mins):Health News:Alzheimer's Association Walk to End Alzheimer's Steps Off Saturday, September 20 in Denver 2Health News:Alzheimer's Association Walk to End Alzheimer's Steps Off Saturday, September 20 in Denver 3Health News:Brain's dynamic duel underlies win-win choices 2Health News:Brain's dynamic duel underlies win-win choices 3Health News:Memantine Discussed in New Comprehensive Patent Search Report by Ark Patent Intelligence Published at MarketPublishers.com 2Health News:Memantine Discussed in New Comprehensive Patent Search Report by Ark Patent Intelligence Published at MarketPublishers.com 3Health News:Gene changes in breast cancer cells pinpointed with new computational method 2Health News:Gene changes in breast cancer cells pinpointed with new computational method 3
    ... ... undergoing leg amputation and detect heart disease earlier if diagnosis and treatment ... legs) were given higher priority by the NHS and there was better ... and Wales, the majority of which are caused by PAD, but there ...
    ... - Breast cancer patients with early stage disease that has ... radiation after mastectomy, because of the low present-day risk of ... could one day change the course of treatment for thousands ... University of Texas M. D. Anderson Cancer. The research, ...
    ... ... Sayer looked around for a good, reliable manufacturer for her award-winning cloth diapers, she did ... manufacturing facility, she also discovered a great way for her company to support its community ... Calgary, Alberta, Canada (PRWEB) ...
    ... may be the culprits, researchers suggest, , FRIDAY, March 5 ... red meat is a risk factor for heart disease, but ... meat -- not unprocessed red meat -- that increases the ... "processed meat" refers to any meat preserved by smoking, curing ...
    ... ... ... , ... , , , , ...
    ... ... ... ... ...
    Cached Medicine News:Health News:Arterial disease awareness cuts heart attacks and leg amputations, claim UK vascular surgeons 2Health News:Arterial disease awareness cuts heart attacks and leg amputations, claim UK vascular surgeons 3Health News:Most early-stage breast cancer patients may not need radiation after mastectomy 2Health News:Most early-stage breast cancer patients may not need radiation after mastectomy 3Health News:Ecobumz Diapers are Going Green While Investing in its Own Community and Employing Women Looking to Enter or Re-enter the Workplace 2Health News:Processed Meat May Harm the Heart 2Health News:Processed Meat May Harm the Heart 3Health News:Processed Meat May Harm the Heart 4Health News:Global AIDS Alliance: U.S. Must Meet Its Obligations to Family Planning 2Health News:Global AIDS Alliance: U.S. Must Meet Its Obligations to Family Planning 3Health News:Endo to Present at Cowen and Company 30th Annual Health Care Conference 2Health News:Endo to Present at Cowen and Company 30th Annual Health Care Conference 3
    Jewelers Forceps, delicate, straight....
    Forceps, pointed, short jaws, suitable for epilation....
    Cilia Forceps, slanted jaws, gold plated....
    Accurate implant size. Polyoxymethylene (POM)....
    Medicine Products: